Top Industry Leaders in the Interleukin Market
AnaptysBio's ANB-038 Phase 2a trial for inflammatory bowel disease (IBD) met primary endpoint: December 2023 success paves the way for further clinical evaluation of ANB-038, a novel engineered IL-10 variant, for treating IBD.
Regeneron's REGN2810 Phase 2 trial for atopic dermatitis (AD) demonstrates positive preliminary data: January 2024 announcement suggests REGN2810's potential in treating AD, with improvements observed in itch and skin lesions.
Janssen Pharmaceutical's IL-10 antibody JNJ-75641378 in a Phase 2 trial for Sjögren's syndrome shows early efficacy: November 2023 development indicates potential for JNJ-75641378 in treating this autoimmune disease affecting salivary and tear glands.
AstraZeneca and Innate Pharma team up for IL-10-based immuno-oncology therapies: December 2023 collaboration combines expertise to develop next-generation IL-10 therapies for cancer treatment.
Roche and Evelo Biosciences partner to discover and develop novel IL-10 agonists: November 2023 collaboration leverages Evelo's AI-powered drug discovery platform to accelerate the development of new IL-10-based treatments.
List of Interleukin-10 Pipeline Key Companies in the Market
- Pfizer Inc.
- Merck & Co.Inc
- Biotest AG
- BioMAS Ltd
- EnGene Inc.
- Leo Pharma
- Anvil Biosciences
- Intrexon Corporation
- P2D Biosciences
- Xalud Therapeutics INC